🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for DMD

A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy. NCT07058662Phase 1, Phase 21 site📍 Beijing Belief BioMed (Beijing) Co., Ltd · Tests: Single dose intravenous of BBM-D101 Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study NCT03373968Phase 2, Phase 339 sites📍 Sacramento📍 San Diego📍 Hartford Italfarmaco · Tests: Givinostat A Remote Study Using Technology to Assess Outcomes in DMD NCT07423026n/a1 site📍 Oxford University of Oxford Biomarker Development for Muscular Dystrophies NCT05019625n/a5 sites📍 Boston📍 Boston📍 Boston Massachusetts General Hospital Swiss Registry for Neuromuscular Disorders NCT05102916n/a19 sites📍 Aarau📍 Bellinzona📍 Lugano University of Bern A Study to Evaluate the Tolerability, Safety and Efficacy of GNR-097 Gene Therapy in Pediatric Patients With Duchenne Muscular Dystrophy NCT07673809Phase 1, Phase 26 sites📍 Minsk📍 Moscow📍 Moscow AO GENERIUM · Tests: GNR-097, Placebo followed by GNR-097 Urinary Titin Biomarker in DMD NCT07332013NA1 site📍 Philadelphia Children's Hospital of Philadelphia · Tests: Descending stair walk DMD Gene Variants and Cardiac Dysfunction in Young Males With Dystrophinopathies NCT07515235n/a1 site📍 Thessaloniki Aristotle University Of Thessaloniki Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy NCT07172971Phase 11 site📍 Nashville Vanderbilt University Medical Center · Tests: SGLT-2 inhibitor, SGLT2 inhibitor Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients NCT07766980Phase 21 site📍 Gainesville University of Florida · Tests: VM100 Nutritional Supplement A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) NCT06138639Phase 1, Phase 215 sites📍 Little Rock📍 Los Angeles📍 Sacramento Solid Biosciences Inc. · Tests: SGT-003 Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders NCT06839469n/a3 sites📍 Palo Alto📍 Boston📍 New York Columbia University A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy NCT07127978n/a9 sites📍 Little Rock📍 Washington D.C.📍 Chicago ITF Therapeutics LLC Invasive Home Ventilation in Denmark NCT07467187n/a1 site📍 Copenhagen Copenhagen University Hospital, Rigshospitalet Natural History of Duchenne Muscular Dystrophy NCT03882827n/a15 sites📍 Brussels📍 Leuven📍 Liège Genethon Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy NCT06641895EARLY Phase 11 site📍 Shanghai Shanghai Jiao Tong University School of Medicine · Tests: BBM-D101 Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT NCT06564974n/a33 sites📍 Phoenix📍 Little Rock📍 Loma Linda Catalyst Pharmaceuticals, Inc. · Tests: Vamorolone Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting NCT07542314Phase 41 site📍 Houston Sarepta Therapeutics, Inc. · Tests: ELEVIDYS, Sirolimus, Glucocorticoids, Antibiotics Research on the Relationship Between Scoliosis, Pain, Quality of Life, and Trunk Muscle Compensation Patterns Among Patients with Duchenne Muscular Dystrophy. NCT06755138n/a1 site📍 Seoul Seoul National University Hospital · Tests: Observational Assessment DMD Voice: Qualitative Interviews With Patients and Caregivers NCT06925269n/a1 site📍 Yardley Red Nucleus Enterprise Solutions, LLC A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE) NCT07160634Phase 37 sites📍 Little Rock📍 Flower Mound📍 Norfolk Solid Biosciences Inc. · Tests: SGT-003, Placebo Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO) NCT07608432Phase 31 site📍 Hillsborough Dyne Therapeutics · Tests: Zeleciment Rostudirsen (DYNE-251), Placebo Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy NCT05933057Phase 329 sites📍 Leuven📍 Vancouver📍 London Italfarmaco · Tests: Givinostat, Placebo Safety and Dystrophin Expression of SPOT-03 in Duchenne Muscular Dystrophy (DMD) Patients NCT07188012EARLY Phase 11 site📍 Shanghai Shanghai Siponuoyin Biotechnology Co Ltd · Tests: SPOT-03 Trial of Cell Based Therapy for DMD NCT06692426Phase 11 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: MyoPAXon, Tacrolimus Wearable Technology to Evaluate Hyperglycemia and HRV in DMD NCT06124196n/a1 site📍 Nashville Vanderbilt University Medical Center · Tests: wearable technology A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort NCT04626674Phase 112 sites📍 Little Rock📍 La Jolla📍 Los Angeles Sarepta Therapeutics, Inc. · Tests: delandistrogene moxeparvovec Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials NCT07674758n/a9 sites📍 Sacramento📍 Washington D.C.📍 Chicago Vanderbilt University Medical Center The Effect of Virtual Reality Applications on Upper Extremity Functions in Patients With Duchenne Muscular Dystrophy NCT07039799NA1 site📍 Istanbul Istanbul University · Tests: Virtual Reality + Conventional Physiotherapy, Conventional Physiotherapy, Formative Usability Evaluation of the VR Reha… A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping NCT07587242Phase 318 sites📍 Westmead📍 Leuven📍 Liège Avidity Biosciences, Inc. · Tests: AOC 1044, Placebo
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy